Pembrolizumab and lenvatinib for recurrent or metastatic cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with cervical cancer that has come back or spread to other parts of the body.
- You may have had up to 2 prior chemotherapy treatments for advanced cancer, and you may have also had immunotherapy or a drug like bevacizumab before.
- You need to have a tumor tissue sample (from a biopsy or surgery) that can be tested for PD-L1.
- You must be in generally good health (able to do daily activities) and have adequate organ function, like your kidneys, liver, and heart.
- You cannot be pregnant or breastfeeding, and if you could become pregnant, you must use highly effective birth control during and for a time after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This trial tests a new combination of drugs for people with advanced cervical cancer that has come back or spread, and who have already tried standard treatments. It aims to see if adding these experimental drugs to lenvatinib is safe and effective.
This trial tests combining two drugs (nituzumab and serplulimab) with focused radiation to treat cervical cancer that has not responded to other therapies. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This trial tests a new drug called Rulonilimab combined with chemotherapy, with or without bevacizumab, as the first treatment for cervical cancer that has spread or come back. It’s for people whose tumors have a specific marker (PD-L1) and who haven’t had other treatments for advanced disease.
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
Hear when a new Cervix Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.